Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026$535 million in cash, cash equivalents and short-term investments as of ...

SUBCUT HF II, a randomized controlled investigator-sponsored trial of at-home subcutaneous furosemide for heart failure–related edema, meets its primary and key secondary endpoints, supporting the ...

Researchers have found in a new randomized trial that among children with bladder and bowel dysfunction, bowel management ...

Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in ...

Bone broth and collagen supplements may have benefits for joints, skin, bones, and gut health. Before taking a supplement or ...

Objectives While exercise adherence is known to vary during cancer treatment, little is known about what predicts these ...

Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10 (41.4%) achieving 25 ...

Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for ...

Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., received regulatory approval from ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 7:20 PM EDTCompany ParticipantsMegan Sniecinski ...